Kairos Pharma Ltd. (NYSE American: KAPA) has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award highlights the company's work in advancing cancer therapeutics designed to address treatment resistance, underscoring Kairos' focus on extending the effectiveness of existing cancer therapies through innovative drug resistance-targeting approaches.
Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
The full press release is available at https://ibn.fm/WuBOf. For the latest news and updates relating to KAPA, visit the company's newsroom at https://ibn.fm/KAPA.
This award matters because drug resistance is a major challenge in oncology, often rendering treatments ineffective over time. Kairos Pharma's approach could potentially expand the utility of existing therapies, offering new hope for patients with resistant cancers. By targeting CD105, the company is addressing a specific mechanism of resistance that may be applicable to multiple cancer types, making this research particularly significant.
The implications of this announcement extend beyond the award itself. It validates Kairos Pharma's scientific strategy and could attract further investment and partnerships. For patients, successful development of ENV-105 could mean more durable responses to treatment and improved outcomes. The recognition also highlights the broader trend in oncology toward overcoming resistance rather than solely developing new drugs.
